Evidence map›Paper›PMID 32241840›Full record

ArticleHaematologica2021

Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm.

Wei Wang, Joseph D Khoury, Roberto N Miranda, Jeffrey L Jorgensen, Jie Xu, Sanam Loghavi, Shaoying Li, Naveen Pemmaraju, Than Nguyen, L Jeffrey Medeiros and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 63 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Proliferation of CD10Journal of medical case reports · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Wei WangDept. of Hematopathology1 and Leukemia2, University of Texas MD Anderson Cancer Center, Houston, USA.
Joseph D KhouryDept. of Hematopathology1 and Leukemia2, University of Texas MD Anderson Cancer Center, Houston, USA.
Roberto N MirandaDept. of Hematopathology1 and Leukemia2, University of Texas MD Anderson Cancer Center, Houston, USA.
Jeffrey L JorgensenDept. of Hematopathology1 and Leukemia2, University of Texas MD Anderson Cancer Center, Houston, USA.
Jie XuDept. of Hematopathology1 and Leukemia2, University of Texas MD Anderson Cancer Center, Houston, USA.
Sanam LoghaviDept. of Hematopathology1 and Leukemia2, University of Texas MD Anderson Cancer Center, Houston, USA.
Shaoying LiDept. of Hematopathology1 and Leukemia2, University of Texas MD Anderson Cancer Center, Houston, USA.
Naveen PemmarajuDept. of Hematopathology1 and Leukemia2, University of Texas MD Anderson Cancer Center, Houston, USA.
Than NguyenDept. of Hematopathology1 and Leukemia2, University of Texas MD Anderson Cancer Center, Houston, USA.
L Jeffrey MedeirosDept. of Hematopathology1 and Leukemia2, University of Texas MD Anderson Cancer Center, Houston, USA.
Sa A WangDept. of Hematopathology1 and Leukemia2, University of Texas MD Anderson Cancer Center, Houston, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematopoietic neoplasm whose immunophenotype remains incompletely characterized, particularly in terms of distinction from reactive plasmacytoid dendritic cells (PDCs). This limitation complicates detection of low-level involvement by BPDCN as well as minimal residual disease (MRD) assessment following therapy. We conducted the current study to characterize the immunophenotype of BPDCN in a cohort of 39 patients, and compared it to reactive PDCs. We found that, in addition to CD56 expression (97%), BPDCN showed a number of aberrancies, including decreased/negative CD38 (82%), positive CD7 (64%), negative CD2 (81%), negative CD303 (56%), increased HLA-DR (69%) and decreased CD123 (78%). Although BPDCN cells were characterized by CD56 expression, reactive PDCs consistently included a CD56-positive subset, ranging 1.3%-20% (median 4.5%) of total PDCs, challenging MRD detection. These CD56+ reactive PDCs, however, were consistently positive for CD2 and CD303, brightly positive for CD38, and negative for CD7, distinctively different from BPDCN. Based on these findings, we set up a 10-color flow cytometry assay for BPDCN and validated it to a sensitivity of 0.01%. This panel was prospectively tested in 19 bone marrow samples from 7 BPDCN patients, and it effectively distinguished BPDCN cells from background reactive PDCs in all cases. In summary, by understanding the immunophenotype of reactive and neoplastic PDCs, BPDCN can be effectively detected by flow cytometry to a very low level using a panel of markers in addition to CD56, and such assay can be used for initial bone marrow workup as well as MRD detection after therapy.

Indexed as

Hematologic NeoplasmsSkin NeoplasmsDendritic CellsFlow CytometryHumansImmunophenotypingNeoplasm, Residual

Identifiers

PMID32241840
PMCPMC8017819
OpenAlexW3015125654

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.